Findings

What do systematic reviews say?

383 questions · 397 findings · 37 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 59 · 14.9%GRADE not reported 11 · 2.8%Very low 70 · 17.6%Low 86 · 21.7%Moderate 110 · 27.7%High 61 · 15.4%

Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) vs ADT only

Withdrawals due to adverse events

Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) may leads to higher discontinuation due to adverse events compared with ADT only (low certainty).

1 finding from 1 review

Taxane‐based chemohormonal therapy for metastatic hormone‐sensitive prostate cancer 2018 · Cochrane Headline outcomes only
RR 79.41 [4.92, 1282.78]
1 study · 385 participants
Low

Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) vs ADT only

All adverse events

Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) may leads to higher all adverse events compared with ADT only (low certainty).

1 finding from 1 review

Taxane‐based chemohormonal therapy for metastatic hormone‐sensitive prostate cancer 2018 · Cochrane Headline outcomes only
RR 1.11 [1.06, 1.17]
1 study · 375 participants
Low

Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) vs ADT only

Quality of life at 12 months (

1 finding from 1 review

Taxane‐based chemohormonal therapy for metastatic hormone‐sensitive prostate cancer 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 790 participants
Low